KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Total Debt (2016 - 2025)

Boston Scientific's Total Debt history spans 17 years, with the latest figure at $11.4 billion for Q4 2025.

  • For Q4 2025, Total Debt rose 6.42% year-over-year to $11.4 billion; the TTM value through Dec 2025 reached $11.4 billion, up 6.42%, while the annual FY2025 figure was $11.4 billion, 6.42% up from the prior year.
  • Total Debt for Q4 2025 was $11.4 billion at Boston Scientific, up from $78.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $11.4 billion in Q4 2025 and bottomed at $23.0 million in Q1 2021.
  • The 5-year median for Total Debt is $9.0 billion (2022), against an average of $5.9 billion.
  • The largest YoY upside for Total Debt was 19229.79% in 2021 against a maximum downside of 99.78% in 2021.
  • A 5-year view of Total Debt shows it stood at $9.1 billion in 2021, then decreased by 1.14% to $9.0 billion in 2022, then rose by 1.26% to $9.1 billion in 2023, then rose by 18.06% to $10.7 billion in 2024, then grew by 6.42% to $11.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Total Debt are $11.4 billion (Q4 2025), $78.0 million (Q3 2025), and $10.7 billion (Q4 2024).